Amylyx Pharmaceuticals (AMLX) Capital Expenditures (2021 - 2025)
Amylyx Pharmaceuticals (AMLX) posted quarterly Capital Expenditures of $86000.0 for Q4 2025, up 330.0% year-over-year from $20000.0 in Q4 2024, and up 258.33% quarter-over-quarter from $24000.0 in Q3 2025.
Amylyx Pharmaceuticals (AMLX) Capital Expenditures (2021 - 2025) Analysis & Trends
Amylyx Pharmaceuticals' Capital Expenditures history runs 5 years deep, the most recent figure standing at $86000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures rose 330.0% year-over-year to $86000.0; the TTM figure through Dec 2025 stood at $138000.0 (down 12.1% YoY), while the FY2025 annual figure was $138000.0, down 12.1% from the prior year.
- Capital Expenditures for Q4 2025 stood at $86000.0, up from $24000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $1.1 million in Q2 2022, with the low at -$19000.0 in Q3 2024.
- The 5-year median for Capital Expenditures is $153000.0 (2021), against an average of $232368.4.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures surged 2342.86% in 2022, then plunged 105.32% in 2024.
- Amylyx Pharmaceuticals' Capital Expenditures stood at $186000.0 in 2021, then soared by 233.33% to $620000.0 in 2022, then sank by 42.58% to $356000.0 in 2023, then tumbled by 94.38% to $20000.0 in 2024, then soared by 330.0% to $86000.0 in 2025.
- Business Quant data shows AMLX's Capital Expenditures at $86000.0 in Q4 2025, $24000.0 in Q3 2025, and $17000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.35 Bn | 4.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 86,000.00 |
| Dec 31, 2025 | 86,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Jun 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 89,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Dec 31, 2023 | 356,000.00 |
| Dec 31, 2023 | 356,000.00 |
| Sep 30, 2023 | 357,000.00 |
| Sep 30, 2023 | 357,000.00 |